Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 07:50pm CET

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
12/08 MERCK : Studies from Merck & Company Update Current Data on Pharmacokinetics [Ph..
12/08DJU.S. Stocks Climb, Extending Rally
12/07 MERCK : New Data from the Largest Ongoing Observational Study Assessing Shingles..
12/07DJMARKET SNAPSHOT : Dow, S&P 500 Set Intraday Records, But Health-care Slumps On T..
12/07 DOW MOVERS : Pfe, wmt
12/07DJMARKET SNAPSHOT : Dow, S&P 500 On Track For Records, But Health-care Slumps On T..
12/07 MERCK : KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality o..
12/06 ADURO BIOTECH : Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immu..
12/06 MERCK : Updated KEYTRUDA® (pembrolizumab) Data in Small Cell Lung Cancer and Mes..
12/06 MERCK : to Participate at the Citi 2016 Global Healthcare Conference
More news
Sector news : Pharmaceuticals - NEC
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/09 CANCER IMMUNOTHERAPY MARKET : 2016 Takeaways And What To Expect In 2017
12/09 VOYAGER THERAPEUTICS UP AFTER POSITI : Not Too Late To Buy
12/09 They're Definitely High On Something
12/08 DRUG PRICING WILL MODERATE INDEPENDE : Stock Winners Will Be Driven By Increases..
12/07 GLOBAL BLOOD THERAPEUTICS : Short-Sellers Could Be In For A Ride
Advertisement
Financials ($)
Sales 2016 39 897 M
EBIT 2016 13 686 M
Net income 2016 5 904 M
Debt 2016 4 610 M
Yield 2016 3,03%
P/E ratio 2016 29,54
P/E ratio 2017 17,53
EV / Sales 2016 4,35x
EV / Sales 2017 4,32x
Capitalization 168 820 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,0 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.15.92%168 820
JOHNSON & JOHNSON9.29%305 407
ROCHE HOLDING LTD.-17.58%193 824
PFIZER INC.-4.15%192 367
NOVARTIS AG-18.49%182 959
SANOFI-2.89%104 027
More Results